CN110446490B - 包含米拉贝隆或其盐的用于调节释放的药剂学组合物 - Google Patents

包含米拉贝隆或其盐的用于调节释放的药剂学组合物 Download PDF

Info

Publication number
CN110446490B
CN110446490B CN201880018616.8A CN201880018616A CN110446490B CN 110446490 B CN110446490 B CN 110446490B CN 201880018616 A CN201880018616 A CN 201880018616A CN 110446490 B CN110446490 B CN 110446490B
Authority
CN
China
Prior art keywords
modified release
pharmaceutical composition
mirabegron
polyethylene oxide
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880018616.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110446490A (zh
Inventor
金秀妍
金暋洙
徐惠珍
朴信政
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Publication of CN110446490A publication Critical patent/CN110446490A/zh
Application granted granted Critical
Publication of CN110446490B publication Critical patent/CN110446490B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
CN201880018616.8A 2017-03-17 2018-03-15 包含米拉贝隆或其盐的用于调节释放的药剂学组合物 Expired - Fee Related CN110446490B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0033944 2017-03-17
KR1020170033944A KR102051132B1 (ko) 2017-03-17 2017-03-17 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
PCT/KR2018/003043 WO2018169325A1 (ko) 2017-03-17 2018-03-15 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물

Publications (2)

Publication Number Publication Date
CN110446490A CN110446490A (zh) 2019-11-12
CN110446490B true CN110446490B (zh) 2023-04-04

Family

ID=63522330

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880018616.8A Expired - Fee Related CN110446490B (zh) 2017-03-17 2018-03-15 包含米拉贝隆或其盐的用于调节释放的药剂学组合物

Country Status (4)

Country Link
JP (2) JP2020510679A (enExample)
KR (1) KR102051132B1 (enExample)
CN (1) CN110446490B (enExample)
WO (1) WO2018169325A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021069944A1 (en) * 2019-10-09 2021-04-15 Alvogen Korea Co., Ltd. Pharmaceutical composition comprising mirabegron and process for manufacturing the same
KR102546923B1 (ko) 2020-03-03 2023-06-26 동광제약 주식회사 미라베그론을 포함하는 제어 방출 제제
KR102794148B1 (ko) * 2021-08-18 2025-04-11 주식회사 삼양홀딩스 룩소리티닙의 경구용 정제 조성물 및 이의 제조 방법
EP4338729A1 (en) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising mirabegron
KR20240102908A (ko) * 2022-12-26 2024-07-03 주식회사 렉스팜텍 아픽사반을 포함하는 서방성 정제
EP4410279A1 (en) 2023-01-25 2024-08-07 Sanovel Ilac Sanayi Ve Ticaret A.S. A film tablet comprising mirabegron

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501022A (ja) * 1998-01-22 2002-01-15 アボット・ラボラトリーズ 副作用の少ない持続放出性チアガビン製剤
CN105232448A (zh) * 2008-09-30 2016-01-13 安斯泰来制药株式会社 控释药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003284700B2 (en) * 2002-11-07 2009-05-28 Astellas Pharma Inc. Remedy for overactive bladder comprising acetic acid anlide derivatives as the active ingredient
CN1905856A (zh) * 2003-12-23 2007-01-31 阿尔扎公司 用于增加受控递送的药物组合物的溶解度的方法和剂型
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
JP5849946B2 (ja) * 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
US20150031734A1 (en) * 2012-03-30 2015-01-29 Astellas Pharma Inc. Pharmaceutical composition containing mirabegron
KR20150045500A (ko) * 2012-08-31 2015-04-28 아스텔라스세이야쿠 가부시키가이샤 경구 투여용 의약 조성물
CN104288116A (zh) * 2014-09-05 2015-01-21 南京华威医药科技开发有限公司 一种米拉贝隆缓释片组合物
KR20170088783A (ko) * 2017-07-07 2017-08-02 지엘팜텍주식회사 미라베그론의 습식과립 조성물
EP3292864A1 (en) * 2017-10-12 2018-03-14 Synthon B.V. Modified release tablet composition comprising mirabegron

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501022A (ja) * 1998-01-22 2002-01-15 アボット・ラボラトリーズ 副作用の少ない持続放出性チアガビン製剤
CN105232448A (zh) * 2008-09-30 2016-01-13 安斯泰来制药株式会社 控释药物组合物

Also Published As

Publication number Publication date
JP2021185139A (ja) 2021-12-09
KR102051132B1 (ko) 2019-12-02
JP2020510679A (ja) 2020-04-09
KR20180106185A (ko) 2018-10-01
WO2018169325A1 (ko) 2018-09-20
CN110446490A (zh) 2019-11-12

Similar Documents

Publication Publication Date Title
CN110446490B (zh) 包含米拉贝隆或其盐的用于调节释放的药剂学组合物
JP7627302B2 (ja) パルボシクリブの固形剤形
KR20230093401A (ko) 붕해가 개선된 경구용 고형 제제 조성물 및 이의 제조 방법
CN108697803A (zh) 透粘膜给药的药物组合物
EP2200591A2 (en) Controlled release pharmaceutical dosage forms of trimetazidine
EA021784B1 (ru) Фармацевтические композиции с длительным высвобождением
JP6768070B2 (ja) 粘膜付着性医薬組成物及びその製造方法
JP2021185139A5 (enExample)
KR20140130736A (ko) 속붕괴성 정제
RU2480240C2 (ru) Композиция с контролируемым высвобождением для производства препарата замедленного высвобождения, содержащего уденафил
JP5694177B2 (ja) 変色及び臭いが抑制されたフィルムコーティング錠
JP5713421B1 (ja) 口腔内崩壊錠
CN108174596A (zh) 包含8-[(3r)-3-氨基-1-哌啶基]-7-(2-丁炔-1-基)-3,7-二氢-3-甲基-1-[4-甲基-2-喹唑啉基)甲基]-1h-嘌呤-2,6-二酮或其药学上可接受的盐的药物组合物
US20060240101A1 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
WO2015152680A1 (en) Granule comprising silodosin, and pharmaceutical composition and formulation comprising same
EP3697392B1 (en) Tablets comprising tamsulosin and solifenacin
Al Hablawi et al. Formulation Variables Influencing the Development of Ketoconazole Gastroretentive Drug Delivery System
EP2744484A1 (en) Pharmaceutical composition comprising 4-[4[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
JP2024067030A (ja) ミラベグロン含有放出制御医薬組成物及びその製造方法
Bühler et al. Generic drug formulations
JP2023071921A (ja) 様々な用量のレナリドミドの経口用錠剤組成物
Devi et al. Formulation and evaluation of gastroretentive floating tablets of diclofenac sodium based on effervescent technology
HUP0600237A2 (en) Pharmaceutical tablet comprising paroxetine mesylate
JP4696210B2 (ja) イソソルビド‐５‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法
Almotairy Formulation Development and Targeted Delivery for BCS II Drugs Using Hot Melt Extrusion Technology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230404